Compare Enveric Biosciences Inc (ENVB) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Monster Beverage Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Monster Beverage Corp trades at $43.6 (market cap $84.00B). The key difference: Monster Beverage Corp is far larger — about 12556.1× Enveric Biosciences Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Monster Beverage Corp for 72 Days on average.
| ENVB | MNST | |
|---|---|---|
Market Cap | $6.69M | $84.00B |
Volume | 41,141 | 8,371,981 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $49.97 |
52-Week Low | $1.27 | $33.16 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.60M | $82.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Monster Beverage (MNST) trades at $43.65, up 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net income margin of 23.08%. Recent news highlights its debt-free balance sheet and international expansion, particularly a 35% surge in overseas sales.
The outlook is mixed: strong fundamentals and analyst consensus support upside to a $98.22 price target, but the stock faces headwinds from rich valuations (P/E 39.7) and technical bearishness. Key risks include inflation pressures and regulatory challenges, such as India's label ban. Institutional sentiment leans bullish, with 52% of analysts rating it Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
